Blue Jet Healthcare

What Blue Jet Healthcare does

Blue Jet Healthcare Limited is an India-based specialty pharmaceutical intermediates and CDMO manufacturer headquartered in Mumbai. Founded in 1973 and listed on NSE/BSE since October 2023, the company operates four interconnected business segments: (i) contrast media intermediates (iodinated APIs such as Iohexol, Iodixanol, Ioversol, Iopamidol, and gadolinium-based agents for MRI), (ii) Saccharin and its salts, where it is India's first and largest manufacturer at 3,000 MT per annum, (iii) protected amino acids and derivatives (FMOCS, BOCs, CBZs, dipeptides, tetrapeptides, linkers) serving as building blocks for GLP-1 and peptide-based APIs, and (iv) CDMO services spanning process development, scale-up, and commercial manufacturing for NCEs and generic APIs.

The company runs multi-ton cGMP-compliant manufacturing facilities in Shahad, Ambernath, and Mahad (Maharashtra) and is constructing a 102-acre greenfield facility at Rambilli, Andhra Pradesh (Rs 2,300 crore investment, operations targeted FY2028-29). Its technology platform covers complex reaction chemistries — acylation, alkylation, bromination, catalytic hydrogenation, Grignard reactions, nitration, oxidation — plus hazardous reagent handling (thionyl chloride, butyl lithium, phosphorous oxychloride). A Hyderabad R&D center (Rs 40 crore, targeted September 2026) and Rs 400 crore FY27 investment in peptides/GLP-1 signal a strategic pivot toward peptide therapeutics supply chains.

Revenue model is B2B direct sales to global pharmaceutical, diagnostic imaging, FMCG, food & beverage, and animal feed customers across 35+ countries, with pricing negotiated through quote-based contracts. FY26 (ended March 2026) revenue was Rs 947.32 crore, down 8.03% YoY, with net profit of Rs 247.82 crore. The company is family-controlled (Arora family), led by Executive Chairman Akshay Bansarilal Arora and Managing Director Shiven Akshay Arora, and recently approved a Rs 1,000 crore QIP to fund growth initiatives.

Name

Blue Jet Healthcare

Legal name

Blue Jet Healthcare Limited

Website

https://bluejethealthcare.com/

Company type

Public

Founded year

1968

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Intermediates and API Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Pharmaceutical intermediates
• Contract manufacturing services
• Contrast media APIs
• Artificial sweetener manufacturing
• Active pharmaceutical ingredients

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. CDMO/Contract Manufacturing: Contract development and manufacturing services for pharmaceutical intermediates and APIs for global innovator companies and generics manufacturers. Revenue generated through project-based contracts, process development fees, and commercial manufacturing supply agreements.
2. Specialty Pharmaceutical Products: Sale of contrast media intermediates and saccharin products to pharmaceutical companies, FMCG companies, food & beverage companies, and animal feed companies. Products sold as finished intermediates or active pharmaceutical ingredients.
3. Pharmaceutical Intermediates & APIs: Sale of pharmaceutical intermediates including protected amino acids, dipeptides, and specialty chemicals for generics and NCE programs. Revenue from commercial supply of 15+ listed intermediates.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels12 records

Core offering

Blue Jet Healthcare is a B2B pharmaceutical CDMO and specialty chemicals manufacturer that develops and produces advanced pharmaceutical intermediates and active pharmaceutical ingredients (APIs) across four business segments: Contrast Media Intermediates (iodinated and gadolinium-based intermediates for medical imaging), Saccharin and its Salts (India's first and largest manufacturer of Saccharin Sodium at 3,000 MT annual capacity), Protected Amino Acids and Derivatives (building blocks for GLP-1 and peptide-based APIs), and end-to-end CDMO Services (contract development and manufacturing from lab to commercialization for NCEs, intermediates, and APIs).

Product overview

Blue Jet Healthcare operates as a CDMO (Contract Development and Manufacturing Organization) and specialty products company with four interconnected business segments: Contrast Media Intermediates (iodinated and gadolinium-based intermediates for medical imaging), Saccharin and its Salts (artificial sweeteners, India's first and largest manufacturer), Protected Amino Acids & Derivatives (building blocks for GLP-1 and peptide-based therapeutics), and CDMO Services (contract manufacturing for pharma intermediates and APIs). The company serves 350+ customers across 35+ countries with integrated capabilities from lab scale to commercial production.

Differentiator

Problem solved

Functional benefit

Products and services

• Contrast Media Intermediates

Quantifiable outcome

• Serves 350+ customers across 35+ countries
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators15 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Divi's Laboratories: India's largest pure-play API and intermediates manufacturer with a strong CDMO franchise. Divi's is a direct peer given Blue Jet's overlapping focus on complex small-molecule APIs, contrast media intermediates, and contract manufacturing for global pharma customers.
• Laurus Labs: Indian API manufacturer with a growing CDMO division serving global innovators. Comparable to Blue Jet in API scale, multi-pharmacopoeia compliance, and integrated development-to-commercialization capabilities.
• Aarti Pharmalabs: Specialty API and intermediates manufacturer with intermediates CDMO exposure. Direct peer given shared focus on complex chemistry intermediates, contrast media adjacencies, and Indian manufacturing for global pharma supply chains.
• Neuland Laboratories: Indian API and CDMO focused on complex small molecules and peptides. Highly comparable to Blue Jet on custom synthesis, complex chemistry platforms, and partnership-based CDMO model.
• Suven Pharmaceuticals: India-based CDMO specializing in NCE development, scale-up, and commercial supply of intermediates and APIs. Direct comparator to Blue Jet's CDMO-Pharma Intermediates & APIs segment.
• Piramal Pharma Solutions: Global CDMO offering integrated drug substance and drug product services. Comparable to Blue Jet on integrated CDMO model, complex chemistry handling, and global pharma customer base.
• Syngene International: India's leading CRO/CDMO offering discovery, development, and manufacturing services. Comparable to Blue Jet on contract research and manufacturing capabilities serving global innovator pharma customers.
• Sai Life Sciences: India-based CDMO offering drug substance and intermediates services across discovery, development, and commercial supply. Direct peer on integrated CDMO model for innovator pharma customers.
• Hikal Limited: Indian manufacturer of APIs, intermediates, and fine chemicals with pharma and crop science exposure. Comparable to Blue Jet on specialty intermediates manufacturing and complex chemistry capabilities.

Broad incumbents

• Jubilant Pharmova: Diversified Indian pharma with CDMO, radiopharma, generics, and proprietary products. Broader incumbent peer given its radiopharma business overlaps with Blue Jet's contrast media intermediates exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bluejethealthcare

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blue Jet Healthcare